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Abstract
Usher syndrome (USH) is a clinically and genetically heterogeneous disorder characterized by visual and hearing
impairments. Clinically, it is subdivided into three subclasses with nine genes identified so far. In the present study, we
investigated whether the currently available Next Generation Sequencing (NGS) technologies are already suitable for
molecular diagnostics of USH. We analyzed a total of 12 patients, most of which were negative for previously described
mutations in known USH genes upon primer extension-based microarray genotyping. We enriched the NGS template either
by whole exome capture or by Long-PCR of the known USH genes. The main NGS sequencing platforms were used: SOLiD
for whole exome sequencing, Illumina (Genome Analyzer II) and Roche 454 (GS FLX) for the Long-PCR sequencing. Long-
PCR targeting was more efficient with up to 94% of USH gene regions displaying an overall coverage higher than 256,
whereas whole exome sequencing yielded a similar coverage for only 50% of those regions. Overall this integrated analysis
led to the identification of 11 novel sequence variations in USH genes (2 homozygous and 9 heterozygous) out of 18
detected. However, at least two cases were not genetically solved. Our result highlights the current limitations in the
diagnostic use of NGS for USH patients. The limit for whole exome sequencing is linked to the need of a strong coverage
and to the correct interpretation of sequence variations with a non obvious, pathogenic role, whereas the targeted
approach suffers from the high genetic heterogeneity of USH that may be also caused by the presence of additional
causative genes yet to be identified.
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Introduction
Usher syndrome (USH) is a group of recessively inherited
disorders characterized by deafness and vision loss. Traditionally,
USH is subdivided into three clinical subclasses. Visual impair-
ment due to Retinitis Pigmentosa (RP) [1] is common to all three
subtypes, which are distinguished based on the severity and
progression of the hearing loss and by the presence or absence of
vestibular symptoms. USH shows genetic heterogeneity: at least 11
distinct loci have been identified and 9 causative genes have been
cloned. Although this classification of USH remains in clinical use,
atypical clinical types have been described that defy this simple
classification.
USH1 is the most severe form of USH: patients display a
congenital and profound deafness associated with vestibular
dysfunction as well as prepubertal onset of progressive RP [2,3].
This form accounts for 30–40% of all USH cases [3,4,5,6,7]. To
date, seven genetic loci for USH1 (USH1B–H) have been mapped
(http://webhost.ua.ac.be/hhh/) and for five of them the corre-
sponding genes have been identified. The genes encode: a) the
actin-based motor protein myosin VIIa (MYO7A, USH1B [5,8,9]),
whose mutations are responsible for the most common USH1
genetic subtype and accounts for approximately 30%–55% of
USH1 cases [7,10,11,12,13]; b) two cadherin-related proteins, i.e.,
otocadherin or cadherin 23 (CDH23, USH1D) [14,15] and
protocadherin 15 (PCDH15,USH1F) [16,17], mutated in 10–35%
and 11–15% of USH1 cases, respectively [3,4,5,7,13,18]; c) two
scaffold proteins, i.e., harmonin (USH1C) [1,19] that account for
6%–15% of cases [6] [13] and SANS (USH1G) [20] responsible for
about 7% of cases [6].
The USH2 type is less severe and is characterized by moderate
to severe congenital deafness, with a high-frequency sloping
configuration. Owing to the overlap between types I and II in
clinical appearance and age of onset, visual symptoms are not
considered reliable predictors of USH type in individual cases
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[2,3,21]. Three genetic loci have been reported so far in USH2
(USH2A, USH2C and USH2D) and the corresponding genes have
been identified. Mutations in the USH2A gene, encoding usherin,
underlie the most common form of USH2 accounting for up to
85–86% of cases [7,13,22,23]. Mutations in the USH2C and
USH2D genes are much rarer [7,13,24,25]. The protein encoded
by the GPR98 gene at the USH2C locus is a member of the
serpentine G-protein coupled receptor superfamily [24]. Defects in
the DFNB31 gene, a PDZ (post-synaptic density, disc-large, Zo-1
protein domains) domain-containing scaffold protein, are respon-
sible for USH2D and nonsyndromic hearing loss (DFNB31)
[25,26]. Finally, USH3 is characterized by variable onset of
progressive hearing loss, variable onset of RP, and variable
impairment of vestibular function and is caused by mutations in
the USH3A (clarin-1) gene, located on 3q21-q25 [27,28]. USH3 is
the less common form of Usher syndrome with a prevalence of 2–
4% within all USH cases [6,7,13].
Identification of the USH causative mutations is important for
early diagnosis, genetic counseling and prenatal diagnosis. Despite
the fact that most Usher syndrome patients can be reliably
grouped into one of the three main clinical classes, a comprehen-
sive molecular diagnostics protocol for Usher syndrome has been
hampered by genetic heterogeneity, the large number of exons to
analyze and by the high costs associated with application of
conventional techniques [29]. Current diagnostic strategies for
Usher syndrome include: a) the use of genotyping microarrays
based on the arrayed primer extension (APEX) method that can
detect the presence of previously reported mutations and has
proved to be an adaptable and affordable mutation screening tool
[29,30,31]; and b) complete exon sequencing of all known Usher
syndrome genes by Sanger sequencing, which was recently
demonstrated to significantly improve diagnostic efficiency for
this condition [10,13], but it is a demanding procedure in terms of
both cost and time.
Newly developed molecular technologies are therefore needed
to facilitate the discovery of underlying gene mutation early in life
and to provide estimation of its prevalence in at risk pediatric
populations thus laying a foundation for its incorporation as an
adjunct to newborn hearing screening programs. During the past
five years, new high-throughput DNA sequencing technologies
collectively referred to as next generation sequencing (NGS) have
emerged [32,33,34]. NGS is nowadays widely used in biomedical
research [35,36,37,38,39], but its applications in molecular
diagnostics are still limited [40,41,42,43]. NGS allows to efficiently
sequence an entire genome, an exome, or specific genomic
regions. The latter can be achieved by using one of several
enrichment methods including long-range PCR (LR-PCR),
fragment-capture using solid surface arrays and in-solution
oligonucleotide capture [44,45,46,47]. In this pilot study, we
report the results obtained by using both exome and targeted
sequencing on human genomic DNA samples from Usher
Syndrome patients.
Results
To evaluate whether the currently available NGS technologies
are ready for USH diagnostics we used: a) Whole exome
sequencing with analysis restricted to known USH genes and b)
targeted resequencing of the known USH genes starting from
long-range PCR products. A schematic overview of the strategy is
shown in Figure 1.
Whole Exome sequencing
We tested nine different Usher patient samples, which
previously turned out to be negative for known mutations in
Usher genes as assessed by APEX microarray screening [31]. In
the analysis, we focused only on the coding exons and the related
splice junction sites of known Usher genes. Each obtained
sequence was analyzed according to a specific workflow as for
the different protocols and platforms used (see Information S1 and
Figures S1 and S2). An average of 12 Gb of sequence was
generated per affected individual (Figure S3). A total of 43.3
million non-duplicated reads could be mapped to the genome. We
found high correlation values (rs.0.9) among coverage depth
positions of samples processed using the same enrichment method.
We decided to consider the minimum and not the mean of
obtained coverage depth to better evaluate the detection of
variations in any coding position. The library and sequencing
chemistry used influenced the overall results in terms of sequence
obtained: on average 58 million reads were obtained for samples
sequenced with SOLiD4 Paired-end protocol (Figure 2, samples
labeled with the ‘‘USH’’ prefix) while 30 million reads were
obtained for SOLiD3 fragment sequencing (Figure 2, samples
labeled with the ‘‘A’’ prefix). The sequence coverage of the USH
genes was comparable with all the Human RefSeq genes regarding
the increase of minimum depth demand (Figure 2A–B). Within the
Usher genomic regions we identified approximately 100 total
sequence variants per sample with an average coverage of 206. In
the process of sequence variant calling, a) we selected those
variants that were located in translated regions; b) we selected
those variants supported by reads on both DNA strands in human
genome; c) we removed those variants deposited in the dbSNP
database (version 135), 1000 human genome dataset, and in our
in-house exome database that includes healthy individuals and
patients with non-ocular conditions. A schematic workflow of our
filtering step procedure and data analysis, similar to the scheme
reported by Wei, X. et al [48] is depicted in Figure S4. This
filtering process narrowed down the observed variations to 1–2 per
samples (Table 1 and Table S3), which were all confirmed by
Sanger Sequencing. An overall number of 12 variations in 5
known USH genes was detected. The variation effect was
predicted following a multi-step analysis available on the Usher
Syndrome Missense Analysis (USMA) website (https://194.167.
35.160/cgi-bin/USMA/USMA.fcgi). Three variants were already
reported in USHbase database as neutral (MYO7A: c.4697C.T),
probably neutral (USH2A: c.14074G.A) and likely pathogenic
(USH2A: c.3176C.T) while the remaining 9 were not described so
far (Table 1). In silico analysis of the variations allowed us to infer
the pathogenic role for 3 out of 9 variants, thanks to the
availability of secondary and 3D structure analysis of the
corresponding protein regions (Table S1).
Notably, only for three samples (A20, USH126, USH103) we
were able to identify two putatively pathogenic sequence variations
in the same gene while for two samples (A26, USH135) we were
not able to identify any putative mutation.
Targeted Resequencing
As an alternative strategy for the molecular analysis of Usher
genes, we tested the efficacy of targeted resequencing. We
designed an in-house enrichment protocol based on 218 Long-
PCR fragments (Table S2) covering all the known exons of the 9
Usher genes. We carried out this analysis on a set of three Usher
patients different from those analyzed by exome sequencing. All
the analyzed patients had been prescreened using the APEX-based
genotyping chip and some putative mutations had already been
identified (Table 2). The obtained Long-PCR amplicons were
Next Generation Sequencing of Usher Syndrome Genes
PLOS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e43799
equimolarly mixed and subsequently split in two parts to use the
same starting material for the different library preparations
according to the NGS platform (see Material and Methods). We
obtained 5 Gb of sequences using the Illumina GAII and 45 Mb
using the GS-FLX platform corresponding to 14.3 millions and
0.22 millions of non-duplicated mappable reads, respectively.
Overall, as expected, this Long-PCR approach yielded a much
higher coverage in Usher genes as compared to whole exome
sequencing and about 94% of the Usher gene exons show a mean
coverage higher than 206 (Figure 3). Since the same long-range
PCR library was analyzed using two different sequencing
platforms, we could also compare the two procedures. Considering
the entire Long-PCR product as target, we can clearly distinguish
a better on-target efficiency of the Illumina GAII Paired-End
Libraries (99% On-Target) compared to GS-FLX (90% On-
Target Figure S5). This difference seems to be increased using the
open source BWA mapping results while platform proprietary
mapping software show a lower Off-Target for the same GS-FLX
data (95% On-Target). Among Long-PCR products, we registered
a similar coverage performance of GS-FLX up to 24–256, but
above that value the curves show a more severe drop for GS-FLX
compared to GAII (Figure 3). We decided to further investigate
the trend by checking for systematic biases in the coverage among
our Long-PCR results. By investigating the coverage distribution
of each single amplicon, we observed an uneven distribution of the
coverage, which could not be ascribed to a random effect. Using
the data from different samples we uncovered a position-
dependent coverage correlation with a Spearman Rank Order
Correlation coefficient of 0.82 rs (Figure S6).
For sequence variant calling, we used the same criteria
described for the analysis of exome-enriched samples. On average,
we obtained a total of 129 sequence variants per sample that
Figure 1. Workflow of the next generation sequencing strategies used. A) whole exome sequencing workflow. Samples have been pre-
screened using an Apex-based Usher genotyping microarray; library preparations prior to enrichment include fragment single reads or Paired-End
preparation. Three different types of enrichment methods have been used; each enrichment probe sets overlap at different extent to the RefSeq
coding regions of Usher genes (horizontal bars). Sequencing protocols include single 50 bp reads on the Solid3 System, single 50 bp read on Solid4
System, Paired-end reads 50 bp+35 bp on Solid4 System. B) Long-PCR sequencing workflow. Samples have been pre-screened using Usher Apex
microarray, Long-PCR approach produced 218 PCR amplicons used as input for the for Fragment and Paired-End library preparation. Sequencing was
performed using both GS-FLX and GAII Systems.
doi:10.1371/journal.pone.0043799.g001
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narrowed down to a few variations with our selection criteria. In
addition to the expected mutations, i.e., those identified by
microarray analysis, two unreported mutations were identified
(Table 2). Sample 1 presents an unreported heterozygous missense
mutation in CDH23: c.1423G.C;p.V475M, classified as proba-
bly-damaging according to Poliphen2 prediction and located in a
domain where other pathogenic variants have previously been
reported [49]. In the case of Sample 3 we identified an unreported
MYO7A variation (MYO7A: c.3827C.A;p.S1276*) that comple-
ments with the previously reported variation (MYO7A: c.77C.A;
p.A26E) identified through APEX screening. Interestingly many
conservation scores (Placental Mammal Basewise Conservation,-
Vertebrate Basewise Conservation, Primate Basewise Conserva-
tion) drastically decrease exactly after the above nonsense
mutation (Figure S7).
Discussion
Molecular diagnosis in Usher syndrome is hindered by
significant genetic heterogeneity, the large size of some of the
Usher genes, and the high number of polymorphic variations in
genes such as MYO7A and USH2A. Furthermore, a digenic
inheritance has been proposed in some cases of Usher syndrome
[10], although not yet universally accepted [13], which further
complicates the elucidation of the molecular basis of genotype-
phenotype correlation. Therefore, the molecular analysis of known
genes using Sanger sequencing is challenging and cannot be
offered routinely [10,13]. The goal of our study was to test the
promising NGS technologies that could be applied to the
molecular diagnosis of Usher syndrome.
To test all the available options for diagnostic NGS, we
investigated to what extent the current NGS technologies can be
used in this process and we compared the efficacy of whole exome
approaches vs. gene-specific approach based on Long–PCR
enrichment. In addition, we obtained sequence data with all
different NGS platforms. To our knowledge, this is the first
attempt to use NGS protocols in the molecular diagnosis of Usher
syndrome.
The first evidence we gathered is that when using whole exome
sequencing the percentage of Usher genes represented ranged
from a maximum of 98% to a minimum of 76% at low sequence
coverage (Figure 2B and Figure S2). However, those values rapidly
decrease as the coverage demand increases. Without a substantial
increase of the number of the sequencing reads and hence of the
sequencing costs/sample, the whole exome approach can be
insufficient for USH diagnosis. For example, setting a minimum
coverage of 306, only 50% of the USH sequences are available for
analysis. In addition, it is also evident that the enrichment protocol
produces an uneven coverage with peaks and falls even in closely
adjacent genomic regions depending on the enrichment protocol
used (see Information S1 and Figures S8 and S9), as shown by high
correlation values between samples processed using the same
enrichment protocol. Even if newer versions of enrichment kits
usually work better than previous ones, when looking at single
Figure 2. Coverage data for whole exome sequencing. A) Relationship between the minimum depth coverage and the extent of basepairs of
RefSeq exons sequenced (shown in percentage). B) Relationship between the minimum depth coverage and the extent of basepairs of Usher exons
sequenced. Solid colored lines represent different samples, x axis: minimum coverage increasing from left to right up to 506; y axis: percentage of
exons sequenced.
doi:10.1371/journal.pone.0043799.g002
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genes it is possible to find some specific exceptions (like in the case
of USH2A) in which the earlier version of the kit gives a better
coverage curve (Figure S3).
In contrast, the Long-PCR-based enrichment leads to an almost
constant curve guaranteeing a higher minimum depth coverage.
Our high correlation value, between samples processed for Long-
PCR, seems to indicate a systematic non uniform distribution in
our approach. This may be due to bias in the PCR products since
no valid correlation with GC composition or length of the
sequenced region can be addressed. Nevertheless, the comparison
of the exon coverage between the Long-PCR and in-solution
method shows that the Long-PCR approach guarantees always a
higher number of exons sequenced for any selected coverage
(Figure 3). This result encourages the development of protocols to
obtain DNA templates prepared by multiplex Long-PCR in order
to decrease costs and workload/sample.
We adopted a high stringency multi-steps filter criteria to select
the pathogenic variants. This approach lowered the number of
false positive variants, although it could raise the number of false
negatives leading to an underestimation of the real number of
variants. The high number of unreported variants (approximately
1 variant per sample) shows that, in the process of designing any
strategy for USH molecular diagnosis, the high prevalence of
novel mutations is a major issue, as already suggested in some
recent publications [10,13]. Sequencing of all known USH exons
and not only the screening of known mutations is required for
proper molecular diagnosis and an accurate genetic counseling. In
this light, we should pay attention to the lack of an adequate
coverage due to the enrichment step, an issue that will be solved
with the technical improvements of the capturing methods.
We observed that NGS of long-PCR products did improve the
detection rate of mutations over APEX screening, but not over the
more demanding Sanger methods [10]. This suggests that the
genetic heterogeneity of USH is much higher and makes the NGS
technologies cost-effective in terms of diagnostic power only in the
cases due to mutations in the known genes. Although NGS can be
envisaged to have multiple applications in clinical diagnostics, the
technology is currently complex and requires attention to technical
issues, including sequencing template enrichment and manage-
ment of massive data. In particular, for lower complexity samples a
point of diminishing returns is reached when the number of counts
per sequence results in oversampling with no increase in data
quality.
Out of the twelve USH patients analyzed, we could genetically
solve five of them as we identified two presumably pathogenic
variants in the same gene (A20, USH100, USH103, USH126, and
Sample3). We identified a single heterozygous putative pathogenic
variant in five other patients, while we could not recognize any
pathogenic sequence variations in the remaining two USH
patients (A26 and USH135, Table 1). Our results are overall in
Table 1. Sequence variants of USH patients identified by whole exome sequencing.
USH Sample (Type) Gene Nucleotide change
Amino Acid
change Enrichment Zygosity Classification(1) Apex
A18 (1) MYO7A c.4411T.C p.S1471P Human all Exon
(50 Mb)
Hetero Unreported N.A.
CLRN1 c.218A.G p.Q73R Human all Exon
(50 Mb)
Hetero Unreported N.A.
A19 (1) MYO7A c.4697C.T p.T1566M Human all Exon
(50 Mb)
Hetero Neutral N.A.
GPR98 c.10577T.C p.M3526T Human all Exon
(50 Mb)
Hetero Unreported N.A.
A20 (2) USH2A c.4663G.T p.G1555C Human all Exon
(50 Mb)
Hetero Unreported N.A.
USH2A c.14219C.A p.A4740D Human all Exon
(50 Mb)
Hetero Unreported N.A.
A26 - - - Human all Exon
(50 Mb)
- - -
USH100 (2) USH2A c.14074G.A p.G4692R Human all Exon
v2(44 Mb)
Hetero UV1 (probably neutral) N.A.
USH2A c.9203delT p.V3068fs Human all Exon
v2(44 Mb)
Hetero Unreported N.A.
USH103 (2(2)) CLRN1 c.619C.T p.R207* Human all Exon
v2(44 Mb)
Homo Unreported N.A.
USH126 (2) PCDH15 c.4880T.C p.V1627A Human all Exon
v2(44 Mb)
Homo Unreported N.A.
USH135 - - - Human all Exon
v2(44 Mb)
- - -
USH10_483 (2) USH2A c.3176C.T p.P1059L Human all Exon
v1(38 Mb)
Hetero UV3 (likely pathogenic) p.P1059L
GPR98 c.11974G.A p.D3992N Human all Exon
v1(38 Mb)
Hetero Unreported N.A.
(1)We annotated the resulting variation according the USHbase database (https://grenada.lumc.nl/LOVD2/Usher_montpellier/USHbases.html) and the 9 variants not
present in the database have been classified as unreported.
(2)Clinical diagnosis compatible with USH type 3.
doi:10.1371/journal.pone.0043799.t001
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agreement with those on larger cohorts of USH patients by Sanger
sequencing [10,13]. The higher percentage of genetically unre-
solved cases (2/12 corresponding to 16% of patients analyzed)
with respect to previous studies can be explained by the fact that
for the whole exome sequencing analysis we selected USH patients
that were not found to harbor any known mutation in USH genes
by APEX screening. We thus enriched our starting dataset for
patients with higher probability to carry mutations in novel, yet to
be identified USH genes.
In conclusion, the constant decrease in costs of NGS procedures
will make them even more attractive in the near future. Even if
nowadays whole genome approaches do not seem to fulfill the
requirements of a complete molecular screening of Usher
Table 2. Sequence variants of USH patients identified by Long-PCR sequencing.




change Enrichment Zygosity Classification(1) Apex
Sample1 (2) CDH23 c.1423G.C p.V475M Long-PCR Hetero N.A. N.A.
USH2A c.2137G.C p.G713R Long-PCR Hetero UV2 (likely neutral) p.G713R
Sample2 (2) USH2A c.2229delG p.E767fs Long-PCR Hetero Pathogenic p.E767fs
CDH23 c.3625A.G p.T1209A Long-PCR Hetero UV2 (likely neutral) p.T1209A
Sample3 (1) MYO7A c.77C.A p.A26E Long-PCR Hetero Pathogenic p.A26E
MYO7A c.3827C.A p.S1276* Long-PCR Hetero Unreported N.A.
1Classification based on the USHbase database https://grenada.lumc.nl/LOVD2/Usher_montpellier/USHbases.html.
doi:10.1371/journal.pone.0043799.t002
Figure 3. Coverage data for long-PCR NGS sequencing. Relationship between the minimum depth coverage and the extent of basepairs of
Usher exons sequenced. Solid colored lines represent sample sequenced on different platforms, whereas the dotted line is the average
representation obtained from the nine sample of Figure 1. x axis indicates the minimum coverage increasing from left to right up to 506while the y
axis indicates the percentage of Usher exon basepairs sequenced.
doi:10.1371/journal.pone.0043799.g003
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Syndrome, they nevertheless remain a potential precious tool for
the identification of new players in disease.
Materials and Methods
Patient selection
The patients examined in this study underwent a screening visit
at the diagnostic centers of either Trieste or Naples that included a
basic ophthalmic consultation, central visual acuity (CVA),
Goldman visual field (GVF), fundus oculi, standard electroreti-
nography (ERG), and a series of periodic control visits. The
patients also provided a detailed medical history and underwent
genetic counseling to identify hereditary patterns. Each patient
underwent a complete ear, nose and throat (ENT) and audio-
vestibular examination, including otomicroscopic examination,
audiometry, and an auditory brainstem response (ABR) for
threshold assessment of patients less than 5 years of age. Blood
samples were collected and genomic DNA was extracted from
blood samples using standard techniques. All patients studied
entered the diagnostic centers of Trieste or Naples and signed an
appropriate consent form for genetic testing as well as forms
related to privacy of data. Approval for the study was obtained by
the Second University of Naples and by IRCCS-Burlo Garofolo of
Trieste Ethics Committees.
Exome Enrichment
For Agilent exome enrichment 3 mg genomic DNA was used.
We used ABI SOLiD optimized kits (Agilent, Santa Clara, CA,
USA), following the manufacturer’s instructions. The different
enrichment kits are reported in Information S1. Briefly, for every
3 mg DNA, we diluted the genomic DNA and, using a Covaris
station, sheered the genomic DNA to 150 base pair fragments.
The purified obtained samples were end repaired, adaptor ligated
and the obtained library amplified according to the SureSelect
Target Enrichment protocol. The final step of hybrid capture
selection provided an enriched library that has been quality
assessed with Agilent 2100 Bioanalyzer. The enriched exome
libraries were subsequently used for e-PCRs following manufac-
turer’s instructions (Life Technologies, Carlsbad, CA, USA), based
on a library concentration of 0.5 pM. DNA sequencing was
performed with the use of the SOLiD system that involves ligation-
based sequencing and a two-base encoding method in which four
fluorescent dyes are used to tag various combinations of
dinucleotide, reducing the risk of false positive determinations.
Differences in the sequencing chemistry used are reported in
Information S1.
Long-PCR Design
Primers were chosen using the web-based program Primer3
(PRIMER3, primer3_www.cgi v 0.2). Each oligo contained 26–
32 nt with a predicted melting temperature higher than 59uC and
lower than 66uC with a GC content lower than 40% where not
possible (14 primers) we selected primers with higher GC contents.
Primers were also checked by BLASTn against the NCBI data
bank genome for specificity (http://www.ncbi.nlm.nih.gov/
BLAST). For long-PCR, 100 ng of genomic DNA was used for
each PCR. We used Takara LA buffer or equivalent (pH .9 at
25uC) with 1.5 mM dNTP (PCR grade) and 3 mM MgCl2 (final
concentrations) and a volume of 20 ml (mix 1). Reactions were
carried out with a DNA Thermocycler System (MWG or MJ
Research) with heated lid. To avoid sample evaporation, aqueous
mixture in each tube was overlaid with 30–40 ml of mineral oil that
was removed by chloroform extraction after the reaction.
After the first denaturation step at 98uC for 1 min, the thermal
cycler was stopped at 85uC and 5 ml of diluted DNA polymerase
(Takara LA Taq) was added. We diluted the polymerase 20-fold
using 16LA buffer. This step was followed by 30 cycles (98u for
10 s, 63uC for 1 min and 68uC for 6 to 12 min). After the PCR,
DNA samples were precipitated with 2.5 vol of ethanol containing
2.5 M ammonium acetate at room temperature and no further
purification was performed. Concentration of PCR product was
measured using the NanoDrop spectrophotometer (NanoDrop,
Wilmington, DE, USA) and verified by agarose gel electrophore-
sis.
The list of primers is available on Table S2. All the obtained
Long-PCR amplicons were equimolarly mixed and subsequently
split in two parts to use the same starting material for the different
library preparation for Illumina GAII and Roche 454 GS FLX.
Long-PCR Sequencing
GS FLX DNA Libraries were made following the manufactur-
er’s protocol. Briefly, 4 mg of the 0.5 mM pooled amplicon solution
was nebulized at 310 kPa for 1 min and purified using the
MiniElute PCR purification kit (Qiagen). Small DNA fragments
were removed using an AMPure PCR purification system
(Agencourt Bioscience, Beverly, MA, USA) and analyzed on an
Agilent 2100 Bioanalyzer. The nebulized DNA was subsequently
end-repaired and phosphorylated using T4 DNA polymerase and
T4 polynucleotide kinase, and oligonucleotide adapters were
ligated to the DNA fragments with DNA ligase. Adapter-modified
fragments were diluted, annealed to capture beads, and clonally
amplified by emulsion PCR. After emulsion PCR, beads with
clonal amplicons were enriched and deposited on a quarter of
Picotiter plate flow cell and sequenced on a Roche 454 GS FLX
platform.
Illumina’s Paired-end libraries were made following the
manufacturer’s protocol with reagents supplied in the Illumina
DNA sample kit. Briefly, 20 ml of the 0.5-mM pooled amplicon
solution was nebulized at 220 kPa for 6 min. The nebulized DNA
was end-repaired using Klenow and T4 DNA polymerases,
phosphorylated with T4 polynucleotide kinase, and adenylated
using Klenow exo-DNA polymerase, and oligonucleotide adapters
were added using DNA ligase. Ligated products were visualized in
a 2% agarose TBE gel, and a 200- to 250-bp size range was
excised and purified using a Qiagen gel extraction kit. The size-
selected, adapter-modified DNA fragments were amplified using
adapter-specific primers 1.1 and 2.1 with Phusion DNA polymer-
ase using the manufacturer’s protocol. The library was purified
prior to quantification using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). A single-flow cell lane was
sequenced on a Illumina Genome Analyzer II. Confirmation of
variants by Sanger sequencing was obtained using standard
protocol. Sequences were run on ABI 3100 DNA analyzer, and
assembled using ABI Prism Seqscape 2.1.
Bioinformatic Sequence data analysis
All next-generation sequencing data were initially processed
using the corresponding instrument software. Roche 454 data
were initially processed using the GSMapper software package
(Roche Inc.) supplied with the GS FLX instrument. High quality
sequencing reads were aligned to the human genome reference
sequence NCBI36/hg18. Variants with respect to NCBI36/hg18
reference sequence were identified with the Newbler software and
the features obtained were remapped to GRCh37/hg19 using
UCSC’s liftOver tool (http://www.ncbi.nlm.nih.gov/genome/
tools/remap) to be directly comparable with the other results.
Illumina Genome Analyzer II data were initially processed using
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the Illumina Sequence Control Software (SCS) with Real Time
Analysis (RTA) and Genome Analyzer Pipeline software supplied
with the instrument. Sequence were aligned to the human genome
reference sequence GRCh37 and variants were identified with
using Illumina’s Consensus Assessment of Sequence and Variation
(CASAVA) software. SOLiD data were initially processed using
the ICS software to obtain primary sequence analysis consisting of
image analysis and basecalling colorspace fasta sequence. Color
space reads were mapped to the GRCh37 reference genome with
the SOLiD bioscope software v1.3 (reference) which utilizes an
iterative mapping approach. Differences in the parameter used for
the different chemistry used are available in Information S1. Single
nucleotide variants were subsequently called by the DiBayes
algorithm using the conservative default call stringency. Small
insertions and deletions were detected using the SOLiD Small InDel
Tool. Called SNP variants and indels were combined and annotated
using a custom analysis pipeline. To spare software biases all the
cross-platforms, comparison has been performed re-analyzing all
the starting data using open-source software. Briefly the raw
sequences obtained from each platform have been aligned to the
human genome reference sequence GRCh37 using BWA [50] and
quality filter before variant calling using Samtools software [51]. In
the process of sequence variant calling, we focused only on variants
included in coding exons and in corresponding canonical splicing
sites of known Usher genes, considering as relevant for splicing sites
investigations only the exons boundaries plus 2 base pairs. We
utilized for further filtering our MYSQL in-house exome database,
which includes sequencing data from 27 healthy individuals and 73
patients with non-ocular conditions. All the SNVs present in the
database with an allele frequency .1% were not regarded as
putative pathogenic mutations.
The Poliphen2 [52] software programs have been used to
predict the influence of any amino acid substitution on the protein
structure and function. PhastCons, and GERP have been used
evaluate the conservation score of each variation. The pathogenic
effect of missense variants was predicted as previously described
[53] following a multi-step analysis [54] and is available in https://
neuro-2.iurc.montp.inserm.fr/cgi-bin/USMA/USMA.fcgi. In ad-
dition, alignments of orthologs are accessible in USMA. Additional
details are present as Information S1.
Supporting Information
Figure S1 Minimum coverage obtained with different
enrichments methods. Panel A shows the percentage of Usher
exons sequenced based on the minimum coverage obtained with
different enrichment methods. Solid colored lines represent mean
values on three independent samples, dashed lines indicate the
mean value+/22 standard deviations from the mean. X axis
indicates the minimum coverage increasing from left to right and is
truncated at 506. Y axis indicates the percentage of Usher exons
basepair sequenced. Arbitrary threshold of 50% is represented
using an horizontal dashed line. B–E) coverage in Usher related
regions that fail in the following Exome enrichments: B, regions
uncovered in SureSelect (50 MB); C, regions uncovered in Agilent
SureSelectV2 (44 MB); D, regions uncovered in Agilent SureSe-
lectV1 (38 MB); E, regions uncovered in TruSEq Exome. F)
Boxplots of different Exome enrichments in regions that fail in
Long-PCR enrichment, G) Boxplots of Long-PCR coverage for
each Exome enrichments uncovered.
(TIF)
Figure S2 Minimum coverage obtained for each Usher
gene. The figure shows base pair percentages of Usher exons
sequenced based on the minimum coverage achieved on a gene-
by-gene basis. Solid colored lines represent the mean values of
three different samples processed using the same enrichment
method. X axis indicates the minimum coverage increasing from
left to right and is truncated at 506. Y axis indicates the
percentage of Usher exons basepair sequenced.
(TIF)
Figure S3 Next Generation Sequencing whole exome
and Long-PCR statistics. A) Counts of sequence obtained
from whole exome sequencing using Solid system and GAII or
Roche GS FLX for Long-PCR. B) Counts of variations obtained
in the Usher genomic regions before and after filter selection.
(TIF)
Figure S4 Flowchart for whole exome process of
screening and identifying variants. All the data used in
the Flowchart represent mean values of 9 independent samples.
(TIF)
Figure S5 Next Generation Sequencing Long-PCR Se-
quencing statistics. Statistic of on target base pairs obtained
from Long-PCR Sequencing using GAII or Solid4 system.
(TIF)
Figure S6 Long-PCR Coverage correlation. The figure
shows the nine Usher genes sequenced using Long-PCR in three
independent samples and the coverage achieved with respect to
the genomic position. X axis indicates the genomic position in base
pairs and Y axis indicates the coverage. For each gene a legend
table report the pair wise correlation value according Spearman’s
rank method confirming a strong position-dependent coverage
correlation.
(TIF)
Figure S7 Genomic regions ofMYO7A variations. A) The
genomic position corresponding to variation MYO7A c.3827C.A
shows a good score for primate, mammal and vertebrate
conservation. Multi protein alignment shows the conservation of
the corresponding S in 36 out of 46 vertebrate. B) The genomic
position corresponding to variation MYO7A c.77C.A shows a
good score for primate, mammal and vertebrate conservation.
Multi protein alignment shows the conservation of the corre-
sponding A in 41 out of 46 vertebrate.
(TIF)
Figure S8 Reads coverage versus relative enrichment
probe positions. We considered only enrichment probes
overlapping known Usher genes. All the data used for the graph
represent mean values of three independent samples.. A) Agilent
SureSelect Human all Exon v1(38 Mb) B) Agilent SureSelect
Human all Exon v2(44 Mb) C) Agilent SureSelect Human all
Exon (50 Mb) D) TrueSeq Exome (68 MB).
(TIF)
Figure S9 Coverage distributions for different enrich-
ment kits in the selected nine known Usher genes. All the
data used for the graph represent mean values of three
independent samples. A) Agilent SureSelect Human all Exon
v1(38 Mb) B) Agilent SureSelect Human all Exon v2(44 Mb) C)
Agilent SureSelect Human all Exon (50 Mb) D) TrueSeq Exome
(68 MB).
(TIF)
Information S1 Supplementary Materials and Methods.
(DOC)
Table S1 List of sequence variants with a presumably
pathogenic effect.
(XLS)
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Table S2 Oligonucleotide primers used to generate long
PCR products.
(XLS)
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